Holding at a dose for an extra 4 weeks before escalating is a medically supported strategy when: Nausea or vomiting persists beyond 2 weeks at the current dose You are unable to eat at least 1,000 calories per day comfortably Dehydration symptoms appear (dark urine, dizziness on standing, dry mouth) You are losing weight faster than 1 to 2 pounds per week on the current dose (aggressive weight loss increases side effect risk) In the STEP trials, delayed escalation did not compromise overall weight loss outcomes at 68 weeks
But the number of researchers who draw 0.4mL when they need 0.8mL, or who cannot translate "4mg" into syringe units at their specific concentration, is staggering
Schwartz wondered if a similar cleavage might be found in GLP-1 (Molteni, Chen)
The way in which GLP-1 drugs are causing weight loss is without question due to suppression of food intaketo satiety, Hayes adds
Xigduo XR is a SGLT2 inhibitor/biguanide that is used to treat type 2 diabetes
These results [36] are particularly significant considering the small sample size and the brief duration of observation [37]
